Clinical Trial Update: Safety of Argatroban Infusion in Conduction Disturbances [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety of argatroban infusion in patients with conduction disturbances; completed with results posted in March 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stable Coronary Artery Disease
• Unstable Angina

Drugs mentioned

• Argatroban (argatroban)

Snippet

Sponsor: Tanabe Pharma GmbH | Conditions: Stable Coronary Artery Disease (CAD), Unstable Angina (Troponin Negative) | Phase 4 | Status: COMPLETED | Results posted: 2024-03-18